Esteve is developing E-5842, a sigma1 opioid receptor ligand, as a potential therapy for psychosis. It has completed phase I trials [344879,346244]. As of May 1999, the site and protocol for phase II schizophrenia trials in the UK had been finalized and these ... ...
